Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of MIRCERA is substantial. |
Clinical Added Value
| no clinical added value |
MIRCERA offers no improvement in actual benefit (level V) compared to the other
erythropoiesis-stimulating agents that are indicated in the correction of anaemia associated with chronic kidney disease. |
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
F4zWRmng5j1aC8xW
Listen
